RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboIn November 2024 Roche and Poseida Therapeutics announced Poseida's acquistion for its pre-clinical "off-the-shelf" allogeneic CAR-T therapy on the strength that the addition of its T- cell engager post CAR-T therapy is able to reactivate a second wave of CAR-T cell proliferation that led to complete remission in patients who had the liquid cancer - multiple myeloma.
.
ONCY has demonstrated that pelareorep is capable of accomplishing a similar complete response in subjects who initially received treatment with a CAR-T therapy + pelareorep and then were given given a second injection of pelareorep at some later point (absent CAR-T), which like above, reactivated a second wave of CAR-T cell proliferation and generated complete responses. However pelareorep's result was ACCOMPLISHED IN THE TREATMENT OF SOLID TUMORS.
Roche acquired pre-clinical Poseida Therapeutics for US$ 1.3 Billion, which follows the previously demonstrated M&A model for preclinical/early stage biopharma companies being acquired in the range of US$1-5 Billion, while late-stage clinical development biopharma companies with 'high-value' assets like ONCY, are being acquired for between US$5 Billion - US$15 Billion